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Review question
How does short stature-for-age in children associate with indicators of cardiovascular and metabolic health?
 
Searches
- NCBI (MeSH and PubMed)
- Scopus
- Web of Science
We are restricting the search to:
1) Studies published in English
2) Studies with human samples only
 
Types of study to be included
Observational studies (longitudinal and cross-sectional) from original articles and short reports.
 
Condition or domain being studied
Short stature has been associated with coronary heart disease in adults (Paajanen et al, 2010), but similar
effects have not been established in children. We aim to identify cardiovascular and metabolic health
indicators that are associated with height-for-age in children. These consist of any measures of
cardiovascular health and metabolic syndrome such as, but not limited to: abdominal obesity; atherogenic
dyslipidaemia; hypertension; hyperglycaemia; insulin resistance; body-mass-index, height-adjusted fat mass,
pulse rate, insulin-resistance, triglycerides, low density lipoprotein cholesterol, high density lipoprotein
cholesterol, and structural and electrical cardiac dysfunction.
Paajaneen et al (2010).European Heart Journal (2010) 31, 1802–1809 doi:10.1093/eurheartj/ehq155
 
Participants/population
Children (male or female) aged 4 to 12 years, without congenital anomalies or known clinical pathologies .
 
Intervention(s), exposure(s)
Metabolic syndrome is defined as a cluster of symptoms that are risk factors for cardiovascular diseases and
type 2 diabetes mellitus. The major components of metabolic syndrome include abdominal obesity;
atherogenic dyslipidemia; hypertension; hyperglycemia; insulin resistance; a proinflammatory state; and a
prothrombotic (thrombosis) state (NCBI-MeSH Definition). 
Cardiovascular disfunction is defined as disfunction of the heart and the blood vessels (NCBI-MeSH
definition).
Early life adverse factors , affecting growth and health in general, may potentiate the onset of one or more
one of these outcomes in childhood.
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Comparator(s)/control
We will use:
a) Cut-off points to define short stature-for-age defined by: 
 i) the WHO standards (children up to 5 years of age) or the WHO references (5+years of age) as -2
standard deviations (SD) of the median value of height-for-age, by sex;
ii) NHANES/CDC references as height-for-age below the 5th percentile
b) Cut-off points for blood pressure, glycemia, and dyslipidaemia reference values set by the American Heart
Association. 
c) Cut-off points for body-mass index-for-age (International Obesity Task Force - IOTF, WHO and Centers
for Disease Control 
d) Cut-off points for abdominal obesity and other remaining metabolic syndrome reference values set by the
WHO.
 
Context
All measurement outcomes must have been taken by trained research staff or a medical professional.
Studies that rely on any subjective, self-reported data will not be included. Outcomes can be measured in
children between ages of 4 and 12 but must be measured before any intervention or treatment. Therefore,
only baseline observational studies will be included.
 
Main outcome(s)
The primary outcome are cardiovascular and metabolic indicators associated with stature-for-age in children.
The secondary outcome consists of any are other measures of metabolic syndrome such as, but not limited
to: abdominal obesity; atherogenic dyslipidaemia; hypertension; hyperglycaemia; insulin resistance; body-
mass-index, height-adjusted fat mass, pulse rate, insulin-resitance, triglycerides, and high-density lipoprotein
cholesterol, ow density lipoprotein cholesterol, and structural or electrical cardiac disfunction.
Timing and effect measures
We will only consider baseline studies in which no interventions have been conducted. We will be narrowing
our time search to the last 10 years, which means that it is unlikely that secular trends in height will bias the
interpretation of the results. 
The mentioning of short-stature or any of the metabolic outcomes are not, per se, a condition for inclusion.
The articles must show that they tested for effects of height upon the cardiovascular and metabolic
outcomes.
 
Additional outcome(s)
None at this stage.
 
Data extraction (selection and coding)
Stage I. Ines Varela-Silva (IVS) will screen for title and abstract according to the eligibility criteria. Articles
that do not meet the inclusion criteria will be excluded. Articles that do not clearly show they meet the
inclusion criteria, from the title and abstract, will pass to stage II. Articles that meet the inclusion criteria will
pass to stage II.
Stage II. Potentially eligible full texts will be obtained and screened by IVS against the inclusion criteria.
Studies not meeting the inclusion criteria will be excluded at this stage, and the reasons for exclusion will be
noted.
Stage III. Nina Mendez (NM) and Emma O’Donnell (EO) will double screen 10% of the full texts included in
stage II. If any discrepancies on eligibility occur at this stage these will be discussed and solved by the entire
team.
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Stage IV. Other key papers identified by the team that have been missed in the searches will be included at
this stage. Full-texts of such papers will be obtained and screened against the inclusion criteria by IVS, and
those meeting the criteria will be included in the review.
Data to be extracted:
- Citation details (title, year of publication, authors, study ID, country of origin,)
- Study details (design, time, duration, setting, sample size, country/region, study objectives)
- Participant details (baseline participant characteristics)
- Journal of publication
- Outcome(s)
- Methods of statistical analysis used to assess the association of interest
- Key statistical analyses results
- Details on any confounding/mediating factors where adjustments were made, for the association of interest.
Data will be extracted and tabulated by IVS. NM will extract and tabulate information on 10% of the papers
included for quality control. If any uncertainty or discrepancies arise after these steps, it will be recorded.
 
Risk of bias (quality) assessment
We will design and use a specific rubric (quantitative and qualitative instrument) to reduce the risks of bias. A
rubric is a guide that list specific criteria for grading and/or scoring academic papers, projects, or tests.
Therefore, the articles will be scored both quantitatively and qualitatively. Specific checklists to score the
included papers and to reduce the risk of bias will be developed by the team. As a starting point, higher
scores will be given to papers which use the standard/references cut-off points, detailed in question 21.
Lower scores will be given to papers that associate stature with any cardiovascular and metabolic syndrome
outcomes, but do not use standard/references cut-off points. The lowest scores will be given to papers that
include associations between height and any of the markers but whose aim was not primarily focused on this
association.
 
Strategy for data synthesis
- A narrative synthesis of the findings will be provided and organised around the association found between
height and cardiovascular and metabolic syndrome indicators.
- A descriptive synthesis of the outcomes will be tabulated and the quantitative scores regarding the quality
of the papers will be provided.
- If suitable (pending the number of articles included for analysis), comparison of the presence/absence of
the main outcomes, across studies, will be developed and discussed.
 
Analysis of subgroups or subsets
If suitable, analysis will be performed by race/ethnic group, gender, socioeconomic status (SES) or poverty
level for any relevant cardiovascular and metabolic syndrome outcomes included in the search criteria.
 
Contact details for further information
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Ines Varela-Silva
m.i.o.varela-silva@lboro.ac.uk
 
Organisational affiliation of the review
Loughborough University
http://lboro.ac.uk
 
Review team members and their organisational affiliations
Dr Ines Varela-Silva. Loughborough University
Dr Emma O'Donnell. Loughborough University
Dr Hugo Azcorra. Cinvestav, Ecologia Humana, Merida
Dr David Oxborough. Liverpool John Moores University
Dr Susana Monserrat-Revillo. Loughborough University
Ms Samantha Sanchez. Cinvestav, Ecologia Humana, Merida
Dr Nina Mendez. Universidad Marista de Merida
 
Anticipated or actual start date
18 February 2019
 
Anticipated completion date
30 September 2019
 
Funding sources/sponsors
None
 
Conflicts of interest
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English
 
Country
England, Mexico
 
Stage of review
Review_Ongoing
 
Subject index terms status
Subject indexing assigned by CRD
 
Subject index terms
Cardiovascular System; Child; Dwarfism; Growth Disorders; Humans
 
Date of registration in PROSPERO
14 February 2019
 
Date of publication of this version
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Details of any existing review of the same topic by the same authors
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 Stage Started Completed
Preliminary searches No No
Piloting of the study selection process Yes No
Formal screening of search results against eligibility criteria Yes Yes
Data extraction No No
Risk of bias (quality) assessment No No
Data analysis No No
 
Versions
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faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration
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